BEIJING--(Marketwire - June 24, 2009) -
| Highlighted Links |
|
|
Over 75 global pharma and biotech experts will present at the annual ChinaTrials: Global Clinical Development Conference & Exhibition in Beijing this November 8-10, as the global biopharmaceutical industry continues to shift its development activities to emerging regions to fuel the next phase of growth.
“Interest in this year’s ChinaTrials Summit is already well ahead of last year’s pace as it’s becoming increasingly clear that China is the most important emerging market for the life sciences industry,” according to Jon E. Liong, Managing Partner of Lychee Group, the organizer. “There’s been a dramatic increase in Western BioPharma companies interested in conducting trials in China, and the number one reason is clearly time savings. Drug developers want to get their medicines on the market the fastest way possible without compromising on quality or safety, and China is helping them do that.”
In addition to time savings, the cost of conducting clinical studies in China can be as much as 75% cheaper than the cost of conducting similar trials in the West. This has drawn the attention of many small and emerging biotech companies, who are particularly vulnerable to the current global credit crisis, with less capital to fund the high costs of drug development.
The conference’s focus is unique, going beyond just China clinical outsourcing topics and directly addressing the challenges facing the hundreds of companies already doing drug development in China. Highlights of the agenda include updates on the fast-changing SFDA guidelines, new regulations on bridging studies for Japan/China, drug safety/quality concerns, and in-depth coverage on conducting oncology trials in China.
The international speaking faculty, consisting of over 40 of the world’s largest companies includes Allergan, Amgen, Baxter, Bayer, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Neuromed, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, and Wyeth.
All the major local and multinational CROs and clinical service providers in China and Asia will also be in attendance including Quintiles, Covance, Parexel, i3 Research, Phase Forward, Paramax International, Excel Pharmastudies, George Clinical, and TigerMed.
To view the full conference agenda, visit www.chinatrialsevent.com or contact Jon E. Liong at jon.liong@lycheegroup.com or call 1-732-917-0664.
ChinaTrials 2009 is organized by Lychee Group, LLC, a specialty media company focused exclusively on China’s life sciences industry.
Contact:
Jon E. Liong
Email Contact
1-732-917-0664
